1. Phylogeny  
   KIT, also known as c‐Kit or the stem cell growth factor receptor (SCFR), is a member of the Class III receptor tyrosine kinase (RTK) family that is evolutionarily conserved across vertebrates (berenstein2015classiiireceptor pages 1-2). Orthologs of KIT have been identified in all mammalian species and in many other vertebrates, indicating its deep evolutionary origin and maintenance from early vertebrate lineages (boissan2000ckitandckit pages 1-2, krupa2002therepertoireof pages 9-10). Within the kinome, KIT belongs to the group of receptor tyrosine kinases that share a modular architecture similar to that of other members such as the platelet-derived growth factor receptor (PDGFR) and FMS-like tyrosine kinase (FLT3), and its grouping has been firmly established in genomic surveys of the human kinome (berenstein2015classiiireceptor pages 1-2, boissan2000ckitandckit pages 1-2). Comparative genomic analyses, as originally reported by Manning and colleagues, place KIT alongside other evolutionarily conserved RTKs whose common ancestry can be traced back to early metazoans (krupa2002therepertoireof pages 9-10). The evolutionary divergence observed between receptor and non-receptor tyrosine kinases is underscored by the unique extracellular architecture of KIT comprising immunoglobulin-like domains that are absent in most cytoplasmic kinases (berenstein2015classiiireceptor pages 1-2, boissan2000ckitandckit pages 1-2). This phylogenetic context underlines KIT’s role as a critical mediator of cell–cell communication in multicellular organisms and its importance in fundamental biological processes such as hematopoiesis, melanogenesis, and gametogenesis (boissan2000ckitandckit pages 1-2).
2. Reaction Catalyzed  
   KIT catalyzes the phosphorylation reaction in which the γ-phosphate from ATP is transferred to tyrosine residues on specific protein substrates, thereby generating ADP, a phosphotyrosine-substituted protein, and a proton (hunter1998thecroonianlecture pages 3-6). This classical reaction is the hallmark of protein-tyrosine kinases and is fundamental to the initiation and propagation of downstream signaling cascades (mazola2008proteinkinasesas pages 1-2). In its active state, KIT phosphorylates substrates such as the regulatory subunit of phosphatidylinositol 3-kinase (PIK3R1), phospholipase C-gamma 1 (PLCG1), the adaptor protein SH2B2 (APS), and the E3 ubiquitin ligase CBL, among others (berenstein2015classiiireceptor pages 12-12). The efficient transfer of the phosphate group is essential for propagating signals that ultimately regulate cellular survival, proliferation, and differentiation (hunter1998thecroonianlecture pages 3-6).
3. Cofactor Requirements  
   The catalytic function of KIT, like other protein kinases, depends on the presence of divalent cations, with magnesium (Mg²⁺) being a critical cofactor (fischer2004thedesignof pages 1-2). Mg²⁺ coordinates with ATP within the kinase active site and stabilizes the transition state during the phosphoryl transfer reaction (fischer2004thedesignof pages 1-2). This requirement for magnesium is a common feature among kinases and is essential to achieve a conformation of the nucleotide that permits the efficient transfer of the phosphate group to tyrosine substrates (fischer2004thedesignof pages 1-2).
4. Substrate Specificity  
   The intrinsic substrate specificity of KIT is determined by the amino acid context surrounding the tyrosine residues that serve as phosphorylation sites (yaronbarir2024theintrinsicsubstrate pages 16-16). Although a single consensus motif has not been universally defined for KIT, studies of the human tyrosine kinome indicate that receptor tyrosine kinases like KIT exhibit preferences dictated by the flanking sequences of the target tyrosine residues (yaronbarir2024theintrinsicsubstrate pages 1-2). Functionally, KIT recognizes and phosphorylates a set of substrates that include PIK3R1 – the regulatory subunit of phosphatidylinositol 3-kinase – and PLCG1, among others (berenstein2015classiiireceptor pages 12-12). The selective phosphorylation of these substrates contributes to the activation of diverse downstream cascades such as the PI3K/AKT, RAS/RAF/MEK/ERK, and STAT pathways (boissan2000ckitandckit pages 3-4, berenstein2015classiiireceptor pages 12-12). In vitro assays and peptide array analyses have been instrumental in elucidating these substrate preferences even though the exact consensus sequence for KIT remains less stringently defined compared to some serine/threonine kinases (yaronbarir2024theintrinsicsubstrate pages 16-16).
5. Structure  
   The structure of KIT is organized into several distinct domains that confer its functional versatility. Its extracellular portion comprises five immunoglobulin-like (Ig-like) domains that collectively mediate specific binding to its ligand, stem cell factor (SCF) (boissan2000ckitandckit pages 1-2, berenstein2015classiiireceptor pages 3-4). Following the extracellular region is the transmembrane domain, a single α-helical segment that anchors the receptor in the plasma membrane and facilitates ligand-induced dimerization (boissan2000ckitandckit pages 1-2). Immediately cytoplasmic to the membrane is the juxtamembrane domain, a region that in the inactive conformation exerts an autoinhibitory effect by stabilizing the receptor in a low-activity state (boissan2000ckitandckit pages 3-4, berenstein2015classiiireceptor pages 3-4). The intracellular region of KIT consists of a bipartite tyrosine kinase domain, which is subdivided into an ATP-binding lobe and a phosphotransferase (catalytic) lobe (boissan2000ckitandckit pages 6-7, boissan2000ckitandckit pages 8-10). Within the tyrosine kinase domain, key structural elements include the activation loop—whose phosphorylation status directly impacts catalytic activity—and the C-helix, which is crucial for coordinating ATP binding and substrate alignment (berenstein2015classiiireceptor pages 3-4, boissan2000ckitandckit pages 10-11). In addition, several mutation hotspots, such as the well-documented Asp816 residue in the activation loop, have been identified; mutations in this region (e.g., Asp816Val) disrupt autoinhibition and lead to constitutive kinase activation (boissan2000ckitandckit pages 11-12, dixit2009sequenceandstructure pages 10-11). Structural studies employing crystallography and computational modeling have provided detailed views of these domains, demonstrating the compact folding of the kinase core and the regulatory influence of the juxtamembrane region in maintaining receptor inactivity until ligand engagement (berenstein2015classiiireceptor pages 3-4, boissan2000ckitandckit pages 13-14).
6. Regulation  
   KIT’s activity is tightly regulated through multiple mechanisms that ensure precise control of its signaling output. In its resting state, the juxtamembrane domain of KIT functions as an autoinhibitory module, preventing unscheduled kinase activation by sterically hindering the proper alignment of the kinase domain for catalysis (boissan2000ckitandckit pages 3-4, berenstein2015classiiireceptor pages 3-4). Binding of the ligand SCF induces receptor dimerization, which relieves this autoinhibition and triggers trans-autophosphorylation of multiple tyrosine residues within the intracellular domain (boissan2000ckitandckit pages 6-7, berenstein2015classiiireceptor pages 1-2). These autophosphorylation events create docking sites for downstream signaling molecules, such as the p85 subunit of PI3K, GRB2, and other adaptor proteins, thereby amplifying and diversifying the signal (boissan2000ckitandckit pages 11-11, boissan2000ckitandckit pages 7-8). In addition, the receptor is subject to negative regulation via protein tyrosine phosphatases, which dephosphorylate critical tyrosine residues and attenuate the signal (boissan2000ckitandckit pages 13-14). KIT’s regulatory mechanisms are further modulated by receptor internalization and ubiquitin-mediated degradation, processes that limit the duration and intensity of the signaling response (boissan2000ckitandckit pages 11-12). Mutations in regulatory domains, particularly within the juxtamembrane and kinase regions, can disrupt these control mechanisms and lead to ligand-independent, constitutive activity of KIT, a phenomenon that is frequently associated with oncogenic transformation in mastocytosis and other hematologic malignancies (boissan2000ckitandckit pages 2-3, dixit2009sequenceandstructure pages 13-14).
7. Function  
   KIT plays a central role in controlling a broad range of cellular processes, largely due to its ability to activate several key intracellular signaling pathways. Upon binding its ligand SCF, KIT undergoes dimerization and autophosphorylation, initiating cascades that regulate cell survival, proliferation, differentiation, and migration (berenstein2015classiiireceptor pages 12-12, boissan2000ckitandckit pages 1-2). KIT is critically involved in hematopoiesis by promoting the survival and proliferation of hematopoietic stem and progenitor cells; it also serves vital functions in the development and function of mast cells, melanocytes, and germ cells (boissan2000ckitandckit pages 3-4, berenstein2015classiiireceptor pages 1-2). Downstream of KIT, activation of the PI3K/AKT pathway occurs through phosphorylation of PIK3R1, which contributes to cell survival and anti-apoptotic signaling (berenstein2015classiiireceptor pages 12-12, boissan2000ckitandckit pages 7-8). Concurrently, the RAS/RAF/MAPK cascade is engaged via adaptor proteins such as GRB2, further promoting cell proliferation and differentiation (boissan2000ckitandckit pages 8-10, berenstein2015classiiireceptor pages 12-12). Moreover, activation of PLCG1 by KIT leads to the production of second messengers such as diacylglycerol and inositol 1,4,5-trisphosphate, which are responsible for calcium mobilization and additional signaling events (boissan2000ckitandckit pages 11-12, berenstein2015classiiireceptor pages 12-12). KIT is also known to stimulate the STAT family of transcription factors (STAT1, STAT3, STAT5A, and STAT5B), thereby directly influencing gene expression programs involved in growth and differentiation (boissan2000ckitandckit pages 14-14, berenstein2015classiiireceptor pages 12-12). Collectively, these pathways underscore the importance of KIT in normal physiological processes such as stem cell maintenance, immune cell development, and pigmentation, as well as its role in oncogenesis when deregulated (amit2007evolvablesignalingnetworks pages 2-3).
8. Other Comments  
   Aberrant KIT signaling is implicated in a variety of diseases, most notably in several hematologic malignancies and in mastocytosis. In many cases, activating mutations—such as the substitution of aspartic acid to valine at residue 816 (D816V)—lead to ligand-independent receptor activation and uncontrolled cell proliferation (boissan2000ckitandckit pages 11-12, dixit2009sequenceandstructure pages 10-11). These mutations alter the conformation of the activation loop and disrupt autoinhibitory interactions, thereby rendering the receptor constitutively active (boissan2000ckitandckit pages 11-12, dixit2009sequenceandstructure pages 10-11). Clinically, such dysregulation has been observed in conditions including gastrointestinal stromal tumors (GIST), mastocytosis, and various forms of leukemia (torkamani2009cancerdrivermutations pages 17-18, hunter1998thecroonianlecture pages 16-17). In parallel, several small molecule inhibitors targeting KIT’s kinase domain have been developed for therapeutic intervention; imatinib mesylate is one of the most well-known examples, although resistance arising from secondary mutations can limit its clinical efficacy (mazola2008proteinkinasesas pages 1-2, kannaiyan2018acomprehensivereview pages 50-55). Other inhibitors under investigation aim to overcome resistance mechanisms by targeting alternative conformations of the kinase domain or modulating downstream signaling pathways (margutti2007aremapkinases pages 5-6, torkamani2008predictionofcancer pages 9-9). These therapeutic strategies highlight the clinical impact of KIT dysregulation and underscore the need for precise molecular diagnostics to guide targeted treatments (torkamani2009cancerdrivermutations pages 17-18).
9. References
10. Berenstein, R. (2015). Class III receptor tyrosine kinases in acute leukemia – biological functions and modern laboratory analysis. Biomarker Insights, 10s3:BMI.S22433. doi:10.4137/bmi.s22433 (pages 1-2, 3-4, 11-12, 12-12).
11. Boissan, M., Feger, F., Guillosson, J.-J., & Arock, M. (2000). C-kit and c-kit mutations in mastocytosis and other hematological diseases. Journal of Leukocyte Biology, 67:135-148. doi:10.1002/jlb.67.2.135 (pages 1-2, 2-3, 3-4, 6-7, 7-8, 8-10, 10-11, 11-11, 11-12, 12-13, 13-14, 14-14, 3-4).
12. Fischer, P.M. (2004). The design of drug candidate molecules as selective inhibitors of therapeutically relevant protein kinases. Current Medicinal Chemistry, 11:1563-1583. doi:10.2174/0929867043365062 (pages 1-2).
13. Mazola, Y., & Rodríguez, R. (2008). Protein kinases as targets for drug design. [Peer-reviewed journal]. doi:10.26153/tsw/7450 (pages 1-2, 2-2).
14. Amit, I., Wides, R., & Yarden, Y. (2007). Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy. Molecular Systems Biology, Dec 2007. doi:10.1038/msb4100195 (pages 2-3, 3-4).
15. Dixit, A., Yi, L., Gowthaman, R., Torkamani, A., Schork, N.J., & Verkhivker, G.M. (2009). Sequence and structure signatures of cancer mutation hotspots in protein kinases. PLoS ONE, 4:e7485. doi:10.1371/journal.pone.0007485 (pages 10-11, 13-14).
16. Hanson, S.M., Georghiou, G., Thakur, M.K., Miller, W.T., Rest, J.S., & Seeliger, M.A. (2019). What makes a kinase promiscuous for inhibitors? Cell Chemical Biology, 26:390-399.e5. doi:10.1016/j.chembiol.2018.11.005 (pages 16-18).
17. Hunter, T. (1998). The Croonian Lecture 1997. The phosphorylation of proteins on tyrosine: its role in cell growth and disease. Philosophical Transactions of the Royal Society of London. Series B, 353:583-605. doi:10.1098/rstb.1998.0228 (pages 3-6, 16-17).
18. Kroiher, M., Miller, M.A., & Steele, R.E. (2001). Deceiving appearances: signaling by “dead” and “fractured” receptor protein-tyrosine kinases. BioEssays, 23:69-76. doi:10.1002/1521-1878(200101)23:1<69::aid-bies1009>3.0.co;2-k (pages 6-11, 21-28).
19. Shah, N.H., Amacher, J.F., Nocka, L.M., & Kuriyan, J. (2018). The Src module: an ancient scaffold in the evolution of cytoplasmic tyrosine kinases. Critical Reviews in Biochemistry and Molecular Biology, 53:535-563. doi:10.1080/10409238.2018.1495173 (pages 1-3, 3-4, 20-22, 27-28, 32-34).
20. Torkamani, A., & Schork, N.J. (2008). Prediction of cancer driver mutations in protein kinases. Cancer Research, 68(6):1675-1682. doi:10.1158/0008-5472.can-07-5283 (pages 9-9).
21. Torkamani, A., Verkhivker, G., & Schork, N.J. (2009). Cancer driver mutations in protein kinase genes. Cancer Letters, 281(2):117-127. doi:10.1016/j.canlet.2008.11.008 (pages 15-17, 17-18).
22. Verkhivker, G.M. (2007). Exploring sequence-structure relationships in the tyrosine kinome space: functional classification of the binding specificity mechanisms for cancer therapeutics. Bioinformatics, 23(15):1919-1926. doi:10.1093/bioinformatics/btm277 (pages 1-1, 1-2, 7-7).
23. Kannaiyan, R., & Mahadevan, D. (2018). A comprehensive review of protein kinase inhibitors for cancer therapy. Expert Review of Anticancer Therapy, 18:1249-1270. doi:10.1080/14737140.2018.1527688 (pages 1-8, 50-55).
24. Margutti, S., & Laufer, S.A. (2007). Are MAP kinases drug targets? Yes, but difficult ones. ChemMedChem. doi:10.1002/cmdc.200600271 (pages 4-5, 5-6).
25. Yaron-Barir, T.M., Joughin, B.A., Huntsman, E.M., Kerelsky, A., Cizin, D.M., Cohen, B.M., et al. (2024). The intrinsic substrate specificity of the human tyrosine kinome. Nature, 629:1174-1181. doi:10.1038/s41586-024-07407-y (pages 1-2, 16-16).
26. Krupa, A., & Srinivasan, N. (2002). The repertoire of protein kinases encoded in the draft version of the human genome: Atypical variations and uncommon domain combinations. Genome Biology, 3:research0066.14. doi:10.1186/gb-2002-3-12-research0066 (pages 9-10).
27. Smith, J.K., Mamoon, N.M., & Duhé, R.J. (2004). Emerging roles of targeted small molecule protein-tyrosine kinase inhibitors in cancer therapy. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics, 14:175-225. doi:10.3727/000000003772462298 (pages 1-2).

References

1. (berenstein2015classiiireceptor pages 12-12): Rimma Berenstein. Class iii receptor tyrosine kinases in acute leukemia – biological functions and modern laboratory analysis. Biomarker Insights, 10s3:BMI.S22433, Jan 2015. URL: https://doi.org/10.4137/bmi.s22433, doi:10.4137/bmi.s22433. This article has 54 citations and is from a peer-reviewed journal.
2. (berenstein2015classiiireceptor pages 3-4): Rimma Berenstein. Class iii receptor tyrosine kinases in acute leukemia – biological functions and modern laboratory analysis. Biomarker Insights, 10s3:BMI.S22433, Jan 2015. URL: https://doi.org/10.4137/bmi.s22433, doi:10.4137/bmi.s22433. This article has 54 citations and is from a peer-reviewed journal.
3. (boissan2000ckitandckit pages 1-2): Mathieu Boissan, Frédéric Feger, Jean-Jacques Guillosson, and Michel Arock. C-kit and c-kit mutations in mastocytosis and other hematological diseases. Journal of Leukocyte Biology, 67:135-148, Feb 2000. URL: https://doi.org/10.1002/jlb.67.2.135, doi:10.1002/jlb.67.2.135. This article has 153 citations and is from a peer-reviewed journal.
4. (boissan2000ckitandckit pages 10-11): Mathieu Boissan, Frédéric Feger, Jean-Jacques Guillosson, and Michel Arock. C-kit and c-kit mutations in mastocytosis and other hematological diseases. Journal of Leukocyte Biology, 67:135-148, Feb 2000. URL: https://doi.org/10.1002/jlb.67.2.135, doi:10.1002/jlb.67.2.135. This article has 153 citations and is from a peer-reviewed journal.
5. (boissan2000ckitandckit pages 11-11): Mathieu Boissan, Frédéric Feger, Jean-Jacques Guillosson, and Michel Arock. C-kit and c-kit mutations in mastocytosis and other hematological diseases. Journal of Leukocyte Biology, 67:135-148, Feb 2000. URL: https://doi.org/10.1002/jlb.67.2.135, doi:10.1002/jlb.67.2.135. This article has 153 citations and is from a peer-reviewed journal.
6. (boissan2000ckitandckit pages 11-12): Mathieu Boissan, Frédéric Feger, Jean-Jacques Guillosson, and Michel Arock. C-kit and c-kit mutations in mastocytosis and other hematological diseases. Journal of Leukocyte Biology, 67:135-148, Feb 2000. URL: https://doi.org/10.1002/jlb.67.2.135, doi:10.1002/jlb.67.2.135. This article has 153 citations and is from a peer-reviewed journal.
7. (boissan2000ckitandckit pages 13-14): Mathieu Boissan, Frédéric Feger, Jean-Jacques Guillosson, and Michel Arock. C-kit and c-kit mutations in mastocytosis and other hematological diseases. Journal of Leukocyte Biology, 67:135-148, Feb 2000. URL: https://doi.org/10.1002/jlb.67.2.135, doi:10.1002/jlb.67.2.135. This article has 153 citations and is from a peer-reviewed journal.
8. (boissan2000ckitandckit pages 14-14): Mathieu Boissan, Frédéric Feger, Jean-Jacques Guillosson, and Michel Arock. C-kit and c-kit mutations in mastocytosis and other hematological diseases. Journal of Leukocyte Biology, 67:135-148, Feb 2000. URL: https://doi.org/10.1002/jlb.67.2.135, doi:10.1002/jlb.67.2.135. This article has 153 citations and is from a peer-reviewed journal.
9. (boissan2000ckitandckit pages 3-4): Mathieu Boissan, Frédéric Feger, Jean-Jacques Guillosson, and Michel Arock. C-kit and c-kit mutations in mastocytosis and other hematological diseases. Journal of Leukocyte Biology, 67:135-148, Feb 2000. URL: https://doi.org/10.1002/jlb.67.2.135, doi:10.1002/jlb.67.2.135. This article has 153 citations and is from a peer-reviewed journal.
10. (boissan2000ckitandckit pages 6-7): Mathieu Boissan, Frédéric Feger, Jean-Jacques Guillosson, and Michel Arock. C-kit and c-kit mutations in mastocytosis and other hematological diseases. Journal of Leukocyte Biology, 67:135-148, Feb 2000. URL: https://doi.org/10.1002/jlb.67.2.135, doi:10.1002/jlb.67.2.135. This article has 153 citations and is from a peer-reviewed journal.
11. (boissan2000ckitandckit pages 7-8): Mathieu Boissan, Frédéric Feger, Jean-Jacques Guillosson, and Michel Arock. C-kit and c-kit mutations in mastocytosis and other hematological diseases. Journal of Leukocyte Biology, 67:135-148, Feb 2000. URL: https://doi.org/10.1002/jlb.67.2.135, doi:10.1002/jlb.67.2.135. This article has 153 citations and is from a peer-reviewed journal.
12. (boissan2000ckitandckit pages 8-10): Mathieu Boissan, Frédéric Feger, Jean-Jacques Guillosson, and Michel Arock. C-kit and c-kit mutations in mastocytosis and other hematological diseases. Journal of Leukocyte Biology, 67:135-148, Feb 2000. URL: https://doi.org/10.1002/jlb.67.2.135, doi:10.1002/jlb.67.2.135. This article has 153 citations and is from a peer-reviewed journal.
13. (fischer2004thedesignof pages 1-2): PM Fischer. The design of drug candidate molecules as selective inhibitors of therapeutically relevant protein kinases. Current Medicinal Chemistry, 11:1563-1583, Jun 2004. URL: https://doi.org/10.2174/0929867043365062, doi:10.2174/0929867043365062. This article has 160 citations and is from a peer-reviewed journal.
14. (amit2007evolvablesignalingnetworks pages 2-3): Ido Amit, Ron Wides, and Yosef Yarden. Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy. Molecular Systems Biology, Dec 2007. URL: https://doi.org/10.1038/msb4100195, doi:10.1038/msb4100195. This article has 194 citations and is from a highest quality peer-reviewed journal.
15. (berenstein2015classiiireceptor pages 1-2): Rimma Berenstein. Class iii receptor tyrosine kinases in acute leukemia – biological functions and modern laboratory analysis. Biomarker Insights, 10s3:BMI.S22433, Jan 2015. URL: https://doi.org/10.4137/bmi.s22433, doi:10.4137/bmi.s22433. This article has 54 citations and is from a peer-reviewed journal.
16. (boissan2000ckitandckit pages 2-3): Mathieu Boissan, Frédéric Feger, Jean-Jacques Guillosson, and Michel Arock. C-kit and c-kit mutations in mastocytosis and other hematological diseases. Journal of Leukocyte Biology, 67:135-148, Feb 2000. URL: https://doi.org/10.1002/jlb.67.2.135, doi:10.1002/jlb.67.2.135. This article has 153 citations and is from a peer-reviewed journal.
17. (dixit2009sequenceandstructure pages 10-11): Anshuman Dixit, Lin Yi, Ragul Gowthaman, Ali Torkamani, Nicholas J. Schork, and Gennady M. Verkhivker. Sequence and structure signatures of cancer mutation hotspots in protein kinases. PLoS ONE, 4:e7485, Oct 2009. URL: https://doi.org/10.1371/journal.pone.0007485, doi:10.1371/journal.pone.0007485. This article has 95 citations and is from a peer-reviewed journal.
18. (dixit2009sequenceandstructure pages 13-14): Anshuman Dixit, Lin Yi, Ragul Gowthaman, Ali Torkamani, Nicholas J. Schork, and Gennady M. Verkhivker. Sequence and structure signatures of cancer mutation hotspots in protein kinases. PLoS ONE, 4:e7485, Oct 2009. URL: https://doi.org/10.1371/journal.pone.0007485, doi:10.1371/journal.pone.0007485. This article has 95 citations and is from a peer-reviewed journal.
19. (hunter1998thecroonianlecture pages 3-6): Tony Hunter. The croonian lecture 1997. the phosphorylation of proteins on tyrosine: its role in cell growth and disease. Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences, 353:583-605, Apr 1998. URL: https://doi.org/10.1098/rstb.1998.0228, doi:10.1098/rstb.1998.0228. This article has 662 citations.
20. (torkamani2008predictionofcancer pages 9-9): Ali Torkamani and Nicholas J. Schork. Prediction of cancer driver mutations in protein kinases. Cancer research, 68 6:1675-82, Mar 2008. URL: https://doi.org/10.1158/0008-5472.can-07-5283, doi:10.1158/0008-5472.can-07-5283. This article has 116 citations and is from a highest quality peer-reviewed journal.
21. (torkamani2009cancerdrivermutations pages 17-18): Ali Torkamani, Gennady Verkhivker, and Nicholas J. Schork. Cancer driver mutations in protein kinase genes. Cancer letters, 281 2:117-27, Aug 2009. URL: https://doi.org/10.1016/j.canlet.2008.11.008, doi:10.1016/j.canlet.2008.11.008. This article has 139 citations and is from a peer-reviewed journal.
22. (kannaiyan2018acomprehensivereview pages 50-55): Radhamani Kannaiyan and Daruka Mahadevan. A comprehensive review of protein kinase inhibitors for cancer therapy. Expert Review of Anticancer Therapy, 18:1249-1270, Oct 2018. URL: https://doi.org/10.1080/14737140.2018.1527688, doi:10.1080/14737140.2018.1527688. This article has 300 citations and is from a peer-reviewed journal.
23. (margutti2007aremapkinases pages 5-6): Simona Margutti and Stefan A. Laufer. Are map kinases drug targets? yes, but difficult ones. ChemMedChem, Aug 2007. URL: https://doi.org/10.1002/cmdc.200600271, doi:10.1002/cmdc.200600271. This article has 62 citations and is from a peer-reviewed journal.
24. (mazola2008proteinkinasesas pages 1-2): Y Mazola Y Mazola, R Rodríguez. Protein kinases as targets for drug design. Unknown journal, 2008.
25. (yaronbarir2024theintrinsicsubstrate pages 1-2): Tomer M. Yaron-Barir, Brian A. Joughin, Emily M. Huntsman, Alexander Kerelsky, Daniel M. Cizin, Benjamin M. Cohen, Amit Regev, Junho Song, Neil Vasan, Ting-Yu Lin, Jose M. Orozco, Christina Schoenherr, Cari Sagum, Mark T. Bedford, R. Max Wynn, Shih-Chia Tso, David T. Chuang, Lei Li, Shawn S.-C. Li, Pau Creixell, Konstantin Krismer, Mina Takegami, Harin Lee, Bin Zhang, Jingyi Lu, Ian Cossentino, Sean D. Landry, Mohamed Uduman, John Blenis, Olivier Elemento, Margaret C. Frame, Peter V. Hornbeck, Lewis C. Cantley, Benjamin E. Turk, Michael B. Yaffe, and Jared L. Johnson. The intrinsic substrate specificity of the human tyrosine kinome. Nature, 629:1174-1181, May 2024. URL: https://doi.org/10.1038/s41586-024-07407-y, doi:10.1038/s41586-024-07407-y. This article has 56 citations and is from a highest quality peer-reviewed journal.
26. (yaronbarir2024theintrinsicsubstrate pages 16-16): Tomer M. Yaron-Barir, Brian A. Joughin, Emily M. Huntsman, Alexander Kerelsky, Daniel M. Cizin, Benjamin M. Cohen, Amit Regev, Junho Song, Neil Vasan, Ting-Yu Lin, Jose M. Orozco, Christina Schoenherr, Cari Sagum, Mark T. Bedford, R. Max Wynn, Shih-Chia Tso, David T. Chuang, Lei Li, Shawn S.-C. Li, Pau Creixell, Konstantin Krismer, Mina Takegami, Harin Lee, Bin Zhang, Jingyi Lu, Ian Cossentino, Sean D. Landry, Mohamed Uduman, John Blenis, Olivier Elemento, Margaret C. Frame, Peter V. Hornbeck, Lewis C. Cantley, Benjamin E. Turk, Michael B. Yaffe, and Jared L. Johnson. The intrinsic substrate specificity of the human tyrosine kinome. Nature, 629:1174-1181, May 2024. URL: https://doi.org/10.1038/s41586-024-07407-y, doi:10.1038/s41586-024-07407-y. This article has 56 citations and is from a highest quality peer-reviewed journal.
27. (hunter1998thecroonianlecture pages 16-17): Tony Hunter. The croonian lecture 1997. the phosphorylation of proteins on tyrosine: its role in cell growth and disease. Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences, 353:583-605, Apr 1998. URL: https://doi.org/10.1098/rstb.1998.0228, doi:10.1098/rstb.1998.0228. This article has 662 citations.
28. (krupa2002therepertoireof pages 9-10): A. Krupa and N. Srinivasan. The repertoire of protein kinases encoded in the draft version of the human genome: atypical variations and uncommon domain combinations. Genome Biology, 3:research0066.1-research0066.14, Nov 2002. URL: https://doi.org/10.1186/gb-2002-3-12-research0066, doi:10.1186/gb-2002-3-12-research0066. This article has 69 citations and is from a highest quality peer-reviewed journal.